|
1
|
Engel J, Eckel R, Schubert-Fritschle G,
Kerr J, Kuhn W, Diebold J, Kimmig R, Rehbock J and Hölzel D:
Moderate progress for ovarian cancer in the last 20 years:
Prolongation of survival, but no improvement in the cure rate. Eur
J Cancer. 38:2435–2445. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
van der Burg ME: Advanced ovarian cancer.
Curr Treat Options Oncol. 2:109–118. 2001. View Article : Google Scholar
|
|
3
|
Watanabe T: Investigational histone
deacetylase inhibitors for non-Hodgkin lymphomas. Expert Opin
Investig Drugs. 19:1113–1127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Horwitz SM: The emerging role of histone
deacetylase inhibitors in treating T-cell lymphomas. Curr Hematol
Malig Rep. 6:67–72. 2011. View Article : Google Scholar
|
|
5
|
Modesitt SC and Parsons SJ: In vitro and
in vivo histone deacetylase inhibitor therapy with vorinostat and
paclitaxel in ovarian cancer models: Does timing matter? Gynecol
Oncol. 119:351–357. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Egger G, Liang G, Aparicio A and Jones PA:
Epigenetics in human disease and prospects for epigenetic therapy.
Nature. 429:457–463. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jones PA and Baylin SB: The fundamental
role of epigenetic events in cancer. Nat Rev Genet. 3:415–428.
2002.PubMed/NCBI
|
|
8
|
Jones PA and Baylin SB: The epigenomics of
cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baylin SB and Ohm JE: Epigenetic gene
silencing in cancer -a mechanism for early oncogenic pathway
addiction? Nat Rev Cancer. 6:107–116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takai N, Desmond JC, Kumagai T, Gui D,
Said JW, Whittaker S, Miyakawa I and Koeffler HP: Histone
deacetylase inhibitors have a profound antigrowth activity in
endometrial cancer cells. Clin Cancer Res. 10:1141–1149. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takai N, Kawamata N, Gui D, Said JW,
Miyakawa I and Koeffler HP: Human ovarian carcinoma cells: Histone
deacetylase inhibitors exhibit antiproliferative activity and
potently induce apoptosis. Cancer. 101:2760–2770. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Timmermann S, Lehrmann H, Polesskaya A and
Harel-Bellan A: Histone acetylation and disease. Cell Mol Life Sci.
58:728–736. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Murdoch WJ: Ovarian surface epithelium,
ovulation and carcinogenesis. Biol Rev Camb Philos Soc. 71:529–543.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Agarwal R and Kaye SB: Ovarian cancer:
Strategies for overcoming resistance to chemotherapy. Nat Rev
Cancer. 3:502–516. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hayashi A, Horiuchi A, Kikuchi N, Hayashi
T, Fuseya C, Suzuki A, Konishi I and Shiozawa T: Type-specific
roles of histone deacetylase (HDAC) overexpression in ovarian
carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates
cell migration with downregulation of E-cadherin. Int J Cancer.
127:1332–1346. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Weichert W, Denkert C, Noske A,
Darb-Esfahani S, Dietel M, Kalloger SE, Huntsman DG and Köbel M:
Expression of class I histone deacetylases indicates poor prognosis
in endometrioid subtypes of ovarian and endometrial carcinomas.
Neoplasia. 10:1021–1027. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shen Y, Shen R, Ge L, Zhu Q and Li F:
Fibrillar type I collagen matrices enhance metastasis/invasion of
ovarian epithelial cancer via β1 integrin and PTEN signals. Int J
Gynecol Cancer. 22:1316–1324. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Isaacs JT, Antony L, Dalrymple SL, Brennen
WN, Gerber S, Hammers H, Wissing M, Kachhap S, Luo J, Xing L, et
al: Tasquinimod is an allosteric modulator of HDAC4 survival
signaling within the compromised cancer microenvironment. Cancer
Res. 73:1386–1899. 2013. View Article : Google Scholar :
|
|
19
|
Geng H, Harvey CT, Pittsenbarger J, Liu Q,
Beer TM, Xue C and Qian DZ: HDAC4 protein regulates HIF1α protein
lysine acetylation and cancer cell response to hypoxia. J Biol
Chem. 286:38095–38102. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Paroni G, Cernotta N, Dello Russo C,
Gallinari P, Pallaoro M, Foti C, Talamo F, Orsatti L, Steinkühler C
and Brancolini C: PP2A regulates HDAC4 nuclear import. Biol Cell.
19:655–667. 2008.
|
|
21
|
Perry RLS, Yang C, Soora N, Salma J,
Marback M, Naghibi L, Ilyas H, Chan J, Gordon JW and McDermott JC:
Direct interaction between myocyte enhancer factor 2 (MEF2) and
protein phosphatase 1α represses MEF2-dependent gene expression.
Mol Cell Biol. 29:3355–3366. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Y, Randall W and Schneider MF:
Activity-dependent and -independent nuclear fluxes of HDAC4
mediated by different kinases in adult skeletal muscle. J Chem
Biol. 168:887–897. 2005.
|
|
23
|
Li J, Chen J, Ricupero CL, Hart RP,
Schwartz MS, Kusnecov A and Herrup K: Nuclear accumulation of HDAC4
in ATM deficiency promotes neurodegeneration in ataxia
telangiectasia. Nat Med. 18:783–790. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
O'Mahony J and Hill C: A real time PCR
assay for the detection and quantitation of Mycobacterium avium
subsp. paratuberculosis using SYBR Green and the Light Cycler. J
Microbiol Methods. 51:283–293. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Krusche CA, Vloet AJ, Classen-Linke I, von
Rango U, Beier HM and Alfer J: Class I histone deacetylase
expression in the human cyclic endometrium and endometrial
adenocarcinomas. Hum Reprod. 22:2956–2966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Weichert W, Röske A, Gekeler V, Beckers T,
Ebert MP, Pross M, Dietel M, Denkert C and Röcken C: Association of
patterns of class I histone deacetylase expression with patient
prognosis in gastric cancer: A retrospective analysis. Lancet
Oncol. 9:139–148. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ozdağ H, Teschendorff AE, Ahmed AA, Hyland
SJ, Blenkiron C, Bobrow L, Veerakumarasivam A, Burtt G,
Subkhankulova T, Arends MJ, et al: Differential expression of
selected histone modifier genes in human solid cancers. BMC
Genomics. 7:902006. View Article : Google Scholar
|
|
28
|
Ahn MY, Kang DO, Na YJ, Yoon S, Choi WS,
Kang KW, Chung HY, Jung JH, Min do S and Kim HS: Histone
deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell
migration via class II histone deacetylase 4 silencing. Cancer
Lett. 28(325): 189–199. 2012. View Article : Google Scholar
|
|
29
|
Stronach EA, Alfraidi A, Rama N, Datler C,
Studd JB, Agarwal R, Guney TG, Gourley C, Hennessy BT, Mills GB, et
al: HDAC4-regulated STAT1 activation mediates platinum resistance
in ovarian cancer. Cancer Res. 71:4412–4422. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mottet D, Pirotte S, Lamour V, Hagedorn M,
Javerzat S, Bikfalvi A, Bellahcène A, Verdin E and Castronovo V:
HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells
through a Sp1-dependent, p53-independent mechanism. Oncogene.
28:243–256. 2009. View Article : Google Scholar
|
|
31
|
Kang ZH, Wang CY, Zhang WL, Zhang JT, Yuan
CH, Zhao PW, Lin YY, Hong S, Li CY and Wang L: Histone deacetylase
HDAC4 promotes gastric cancer SGC-7901 cells progression via p21
repression. PLoS One. 9:e988942014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fenner J, Stacer AC, Winterroth F, Johnson
TD, Luker KE and Luker GD: Macroscopic stiffness of breast tumors
predicts metastasis. Sci Rep. 4:55122014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kaemmerer E, Melchels FP, Holzapfel BM,
Meckel T, Hutmacher DW and Loessner D: Gelatine
methacrylamide-based hydrogels: an alternative three-dimensional
cancer cell culture system. Acta Biomater. 10:2551–2562. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Curry JM, Sprandio J, Cognetti D,
Luginbuhl A, Bar-ad V, Pribitkin E and Tuluc M: Tumor
microenvironment in head and neck squamous cell carcinoma. Semin
Oncol. 41:217–234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cohen AL, Piccolo SR, Cheng L, Soldi R,
Han B, Johnson WE and Bild AH: Genomic pathway analysis reveals
that EZH2 and HDAC4 represent mutually exclusive epigenetic
pathways across human cancers. BMC Med Genomics. 6:352013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu F, Pore N, Kim M, Voong KR, Dowling M,
Maity A and Kao GD: Regulation of histone deacetylase 4 expression
by the SP family of transcription factors. Mol Biol Cell.
17:585–597. 2006. View Article : Google Scholar :
|
